Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H21N4O9P |
Molecular Weight | 456.3438 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)C3=NC(=O)NC(=O)C3=N2
InChI
InChIKey=FVTCRASFADXXNN-SCRDCRAPSA-N
InChI=1S/C17H21N4O9P/c1-7-3-9-10(4-8(7)2)21(15-13(18-9)16(25)20-17(26)19-15)5-11(22)14(24)12(23)6-30-31(27,28)29/h3-4,11-12,14,22-24H,5-6H2,1-2H3,(H,20,25,26)(H2,27,28,29)/t11-,12+,14-/m0/s1
DescriptionCurator's Comment: Description was created based on several sources, including http://rupharma.com/cytoflavin/ and https://ods.od.nih.gov/factsheets/Riboflavin-HealthProfessional/
Curator's Comment: Description was created based on several sources, including http://rupharma.com/cytoflavin/ and https://ods.od.nih.gov/factsheets/Riboflavin-HealthProfessional/
Flavin mononucleotide, or riboflavin-5′-phosphate, is a biomolecule produced from riboflavin by the enzyme riboflavin kinase and functions as prosthetic group of various oxidoreductases including NADH dehydrogenase as well as cofactor in biological blue-light photo receptors. Riboflavin (Vitamin B 2) (as riboflavin 5-phosphate sodium) is an ingredient of the FDA approved composition Infuvite Adult, indicated as a daily multivitamin maintenance supplement for adults and children aged 11 and older receiving parenteral nutrition. Infuvite Adult is also indicated in other situations where administration by the intravenous route is required. Such situations include surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states, which may provoke a “stress” situation with profound alterations in the body’s metabolic demands and consequent tissue depletion of nutrients. Flavin mononucleotide is also a component of Cytoflavin, used for the treatment of consequences of cerebral infarction, for the treatment of atherosclerosis, encephalopathy, neurasthenia. Cytoflavin is marketed in Russian Federation.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7452254
Curator's Comment: Penetrant in rabbits
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Thymidylate synthase-dihydrofolate reductase, Cryptosporidium hominis Sources: http://www.ncbi.nlm.nih.gov/pubmed/19059777 |
55.0 µM [IC50] | ||
Target ID: GO:0006116 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26721206 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Infuvite Adult Approved UseInfuvite Adult is indicated for the prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition Launch Date2003 |
|||
Sources: http://rupharma.com/cytoflavin/ |
Primary | Cytoflavin Approved UseIndicated for the treatment of consequences of cerebral infarction, for the treatment of atherosclerosis, encephalopathy, neurasthenia |
||
Sources: http://rupharma.com/cytoflavin/ |
Primary | Cytoflavin Approved UseIndicated for the treatment of consequences of cerebral infarction, for the treatment of atherosclerosis, encephalopathy, neurasthenia |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1209.4 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
11.6 mg single, intravenous dose: 11.6 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
206.7 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
308.2 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
217.7 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
532.1 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
11.6 mg single, intravenous dose: 11.6 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
886.4 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
981.6 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
883.9 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8604671/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
RIBOFLAVIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
PubMed
Title | Date | PubMed |
---|---|---|
Nutritional status and physical working capacity. | 1982 |
|
Riboflavin status in infants born in rural Gambia, and the effect of a weaning food supplement. | 1982 |
|
The effect of periconceptional supplementation on blood vitamin concentrations in women at recurrence risk for neural tube defect. | 1983 Mar |
|
Comparison of riboflavin, vitamin A, and zinc status of Chinese populations at high and low risk for esophageal cancer. | 1985 |
|
Folic acid, riboflavin, thiamine, and vitamin B-6 status of a group of first-time blood donors. | 1998 Nov |
|
Riboflavin levels in maternal milk: the influence of vitamin B2 status during the third trimester of pregnancy. | 1999 Aug |
|
Elevation of serum riboflavin carrier protein in breast cancer. | 1999 Nov |
|
Predictors of micronutrient status among six- to twelve-month-old breast-fed Ghanaian infants. | 2000 Feb |
|
Longitudinal vitamin and homocysteine levels in normal pregnancy. | 2001 Jan |
|
Abnormal vitamin levels in patients receiving home total parenteral nutrition. | 2001 Nov-Dec |
|
Anti-oxidant vitamins and steroid responsive nephrotic syndrome in Indian children. | 2002 Oct |
|
FKF1 is essential for photoperiodic-specific light signalling in Arabidopsis. | 2003 Nov 20 |
|
Improving the bacteriological safety of platelet transfusions. | 2004 Jan |
|
Efficacy of twice-weekly multiple micronutrient supplementation for improving the hemoglobin and micronutrient status of anemic adolescent schoolgirls in Bangladesh. | 2005 Oct |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/infuvite-adult.html
Curator's Comment: Can also be taken orally in Cytoflavin formulation http://vitamedd.com/en/pages/1342999
The starting dose of Infuvite Adult is one 10 mL daily dose that is prepared by transferring the content of vial 1 into the content of vial 2 to provide 10 single doses. One 10 mL dose is then added directly to the intravenous fluid. Patients with multiple vitamin deficiencies or with increased vitamin requirements may need multiple daily dosages as indicated.
Each 5 mL of Vial 1* contains 3.6 mg of Riboflavin (Vitamin B 2) (as riboflavin 5-phosphate sodium)
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/19059777
Flavin mononucleotide inhibited Cryptosporidium hominis TS-DHFR with IC50 55 uM
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
53648-2
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
||
|
FDA ORPHAN DRUG |
342311
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
||
|
DSLD |
4337 (Number of products:1)
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
||
|
DSLD |
203 (Number of products:536)
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
||
|
LOINC |
79393-5
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
||
|
NCI_THESAURUS |
C26017
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB03247
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
643976
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
C61925
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
SUB35224
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
146-17-8
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
1925821
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
D005486
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
17621
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
7N464URE7E
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
DTXSID8023559
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
SUB35561
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
m5393
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | Merck Index | ||
|
FLAVIN MONONUCLEOTIDE
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
2374
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
7N464URE7E
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
100000128322
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY | |||
|
205-664-7
Created by
admin on Fri Dec 15 15:01:56 GMT 2023 , Edited by admin on Fri Dec 15 15:01:56 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)